# A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects

> **NCT00002353** · PHASE1 · COMPLETED · sponsor: **United Biomedical**

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** P3C541b Lipopeptide

## Key facts

- **NCT ID:** NCT00002353
- **Lead sponsor:** United Biomedical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002353, "A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00002353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*